ADVB Overview

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip.

Wall Street analysts forecast ADVB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADVB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Advanced Biomed Inc revenue for the last quarter amounts to -396.64K USD, increased 41.63

Advanced Biomed Inc. EPS for the last quarter amounts to 351036.00 USD, decreased -141.70

Advanced Biomed Inc (ADVB) has 31 emplpoyees as of March 12 2026.

Today ADVB has the market capitalization of 7.07M USD.